A combination of the US drugmaker’s monoclonal antibodies bamlanivimab and etesevimab has been given approval for restricted use in emergency situations in hospital settings in adults.
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.